LianBio (LIAN) Competitors $0.06 +0.00 (+8.35%) As of 09/23/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendFDA EventsSEC FilingsTrendsBuy This Stock LIAN vs. NEUP, FBLG, PASG, QTTB, PMN, CING, AYTU, SNYR, TAOX, and CLSDShould you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Neuphoria Therapeutics (NEUP), FibroBiologics (FBLG), Passage Bio (PASG), Q32 Bio (QTTB), Promis Neurosciences (PMN), Cingulate (CING), Aytu BioPharma (AYTU), Synergy CHC (SNYR), Synaptogenix (TAOX), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. LianBio vs. Its Competitors Neuphoria Therapeutics FibroBiologics Passage Bio Q32 Bio Promis Neurosciences Cingulate Aytu BioPharma Synergy CHC Synaptogenix Clearside Biomedical LianBio (NASDAQ:LIAN) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings. Do institutionals & insiders hold more shares of LIAN or NEUP? 74.8% of LianBio shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to LIAN or NEUP? In the previous week, Neuphoria Therapeutics had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score. Company Overall Sentiment LianBio Neutral Neuphoria Therapeutics Neutral Which has more risk and volatility, LIAN or NEUP? LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Is LIAN or NEUP more profitable? Neuphoria Therapeutics' return on equity of 0.00% beat LianBio's return on equity.Company Net Margins Return on Equity Return on Assets LianBioN/A -33.17% -30.19% Neuphoria Therapeutics N/A N/A N/A Which has better earnings and valuation, LIAN or NEUP? Neuphoria Therapeutics has higher revenue and earnings than LianBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLianBioN/AN/A-$110.29M-$0.81-0.07Neuphoria Therapeutics$10K2,152.60-$15.49MN/AN/A Do analysts recommend LIAN or NEUP? Neuphoria Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 144.54%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than LianBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNeuphoria Therapeutics beats LianBio on 9 of the 11 factors compared between the two stocks. Get LianBio News Delivered to You Automatically Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIAN vs. The Competition Export to ExcelMetricLianBioBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.45M$226.81M$5.77B$10.41BDividend YieldN/A3.78%5.68%4.62%P/E Ratio-0.0731.8676.0426.42Price / SalesN/A4,682.02521.33168.33Price / CashN/A13.1937.5661.52Price / Book0.02117.2712.876.39Net Income-$110.29M-$90.99M$3.29B$271.13M7 Day PerformanceN/A0.22%0.80%0.93%1 Month PerformanceN/A16.39%4.91%7.52%1 Year PerformanceN/A595.95%67.75%30.06% LianBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIANLianBioN/A$0.06+8.3%N/A-80.4%$6.45MN/A-0.07110Gap UpNEUPNeuphoria Therapeutics1.9943 of 5 stars$12.51+3.6%$28.00+123.8%N/A$22.69M$10K0.00N/AUpcoming EarningsFBLGFibroBiologics2.6504 of 5 stars$0.53-1.8%$12.50+2,260.7%-79.4%$22.59MN/A-1.4710PASGPassage Bio3.3791 of 5 stars$7.27+4.6%$75.67+940.8%-39.2%$22.09MN/A-0.40130Gap DownQTTBQ32 Bio2.163 of 5 stars$1.88+3.9%$12.17+547.2%-95.8%$22.08M$1.16M-0.4439PMNPromis Neurosciences2.985 of 5 stars$0.42+1.3%$4.33+922.0%-68.1%$21.68MN/A-2.025News CoverageCINGCingulate2.461 of 5 stars$3.93+0.5%$26.25+567.9%-23.6%$21.16MN/A-0.9620Analyst RevisionGap UpAYTUAytu BioPharma3.7593 of 5 stars$2.34+0.4%$10.00+327.4%-15.2%$20.92M$81M-3.25160Trending NewsEarnings ReportGap DownHigh Trading VolumeSNYRSynergy CHC3.9819 of 5 stars$2.35+6.3%$10.00+325.5%N/A$20.87M$34.83M6.1840TAOXSynaptogenix0.1814 of 5 stars$6.03+1.3%N/AN/A$20.75MN/A-0.304CLSDClearside Biomedical2.0734 of 5 stars$3.57-9.6%$63.00+1,664.7%-76.7%$20.68M$1.66M-0.6430High Trading Volume Related Companies and Tools Related Companies NEUP Alternatives FBLG Alternatives PASG Alternatives QTTB Alternatives PMN Alternatives CING Alternatives AYTU Alternatives SNYR Alternatives TAOX Alternatives CLSD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIAN) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
